To study the impact of corona virus pandemic on the cancer care of patients with urological cancers.
- Registration Number
- CTRI/2020/09/027642
- Lead Sponsor
- Dr Ganesh Bakshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients registered with TMH Uro-Oncology DMG with known or suspected Prostate/Bladder/Kidney cancers. These will include new patients registered before and after the lockdown started upto one month post complete lifting of the lockdown and
2.Who fall in one of the following categories:
i.Registered before lockdown and were in the investigations phase
ii.Registered before lockdown and were in the treatment planning phase
iii.Patients who had their treatment planned before lockdown and were having prior appointment for a scheduled therapy at TMH during lock down period.
iv.Patients who had completed their treatment before lockdown and were having prior appointment for a scheduled follow-up at TMH during lock down period.
v.All patients who: were advised follow-up (but no appointment taken by patient) for a date during the lockdown and also did not consult on phone/email and visit the Uro-oncology DMG within one month of the complete lifting of the lockdown and whose names may or may not generated from any of the lists (IT/OPD/ROIS/MOIS) will be considered as eligible for the study.
vi.All patients who register and visit the Uro-oncology DMG within one month of the complete lifting of the lockdown and who have any report (indicative of cancer) or referral letter for TMH but whose names were not generated from any of the lists (IT/OPD/ROIS/MOIS) will be considered as eligible for the study, if the report or referral letter is dated anytime from March 2020 onwards.
vii.The new patients who visited TMH personally or consulted on phone/email during lockdown and were advised investigations but could not make it to the treatment planning joint clinic (for any of the following reasons like: their inability to visit TMH due to lockdown / inability to visit TMH due to patient of relative suffering from Covid / non-functional diagnostic services at TMH / financial reasons / non-functional diagnostic or treatment services at outside TMH hospitals) will be considered as eligible if they do visit TMH or could be contacted on phone within one month of complete lifting of lockdown.
The case numbers of patients will be captured from the IT department and OPD records. Additionally, case numbers of patients waitlisted for surgery, radiation therapy and chemotherapy would be sought from EMR, ROIS, MOIS and other paper documented records
1.Not falling in above criteria,
2.The new patients who visited TMH personally or consulted on phone/email and were advised investigations but could not make it to the treatment planning joint clinic (for any of the following reasons like: their inability to visit TMH due to lockdown / inability to visit TMH due to patient of relative suffering from Covid / non-functional diagnostic services at TMH / financial reasons / non-functional diagnostic or treatment services at outside TMH hospitals) will be considered as not eligible if they do not visit even within one month of complete lifting of lockdown.
3.All patients who register and visit the Uro-oncology DMG within one month of the complete lifting of the lockdown and who have any report (indicative of cancer) or referral letter for TMH but whose names were not generated from any of the lists (IT/OPD/ROIS/MOIS) will be considered as not eligible for the study, if the report or referral letter is dated before March 2020 will not be eligible for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the impact of the corona virus pandemic on the cancer care of the Urological cancer patients of the Uro-oncology DMG, TMHTimepoint: one month
- Secondary Outcome Measures
Name Time Method 1.document <br/ ><br>i.decline in number of new and follow up patients seen in OPD <br/ ><br>ii.percentage suboptimal pre-treatment evaluation <br/ ><br>iii.number of patients contracted COVID <br/ ><br>iv.diagnostics and management policies implemented lockdown. <br/ ><br>v.reasons for non-compliance <br/ ><br>2.assess <br/ ><br>i.patient compliance rates to treatment <br/ ><br>ii.change in time to treatment planning JC and usual treatments <br/ ><br>3.study <br/ ><br>i.overall impact on patient related outcomes <br/ ><br>ii.study various difficulties faced by patients <br/ ><br>Timepoint: three months